Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Progestogen (Retroprogesterone)

Dydrogesterone

Brand names: Duphaston

Dydrogesterone is an orally active progestogen used for progesterone-deficiency conditions such as dysfunctional uterine bleeding, dysmenorrhoea, endometriosis, and as the progestogen component of hormone replacement therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively binds progesterone receptors to produce secretory transformation of an oestrogen-primed endometrium, without significant oestrogenic, androgenic or corticoid activity.

Prescribing in practice

  • When used to oppose oestrogen in hormone replacement therapy, adequate progestogen exposure is needed to protect the endometrium and reduce the risk of endometrial hyperplasia.
  • Exclude pregnancy where appropriate and assess for hormone-sensitive conditions before starting.
  • Investigate any unexplained or breakthrough vaginal bleeding that occurs during treatment.

Monitoring

No routine laboratory monitoring is required; review bleeding pattern, symptom control and ongoing indication, and investigate unexpected bleeding.

Counselling the patient

  • Take the tablets as scheduled for your particular indication.
  • Report any unusual, heavy or persistent vaginal bleeding.
  • Attend follow-up to review whether continued treatment is needed.

Evidence & guidelines

Dydrogesterone is a well-established progestogen used for endometrial protection in HRT and for a range of progestogen-responsive gynaecological conditions; prescribe per current prescribing references.

Reference: PRISM trial (Coomarasamy et al. NEJM 2019); PROMISE trial (Coomarasamy et al. NEJM 2015); NICE NG126; RCOG Recurrent Miscarriage Guideline (2023); SPC Duphaston; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).